{
    "abstract": "In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life.",
    "bibjson": {
        "author": [
            {
                "initials": "L",
                "lastname": "Shan",
                "name": "Shan L"
            },
            {
                "initials": "NV",
                "lastname": "Dyk",
                "name": "Dyk NV"
            },
            {
                "initials": "N",
                "lastname": "Haskins",
                "name": "Haskins N"
            },
            {
                "initials": "KM",
                "lastname": "Cook",
                "name": "Cook KM"
            },
            {
                "initials": "KL",
                "lastname": "Rosenthal",
                "name": "Rosenthal KL"
            },
            {
                "initials": "R",
                "lastname": "Mazor",
                "name": "Mazor R"
            },
            {
                "initials": "S",
                "lastname": "Dragulin-Otto",
                "name": "Dragulin-Otto S"
            },
            {
                "initials": "Y",
                "lastname": "Jiang",
                "name": "Jiang Y"
            },
            {
                "initials": "H",
                "lastname": "Wu",
                "name": "Wu H"
            },
            {
                "initials": "WF",
                "lastname": "Dall'Acqua",
                "name": "Dall'Acqua WF"
            },
            {
                "initials": "MJ",
                "lastname": "Borrok",
                "name": "Borrok MJ"
            },
            {
                "initials": "MM",
                "lastname": "Damschroder",
                "name": "Damschroder MM"
            },
            {
                "initials": "V",
                "lastname": "Oganesyan",
                "name": "Oganesyan V"
            }
        ],
        "identifier": [
            {
                "id": "10.1038/s42003-021-02565-5",
                "type": "doi"
            },
            {
                "id": "34497355",
                "type": "pubmed"
            }
        ],
        "issue": [
            "1"
        ],
        "journal": {
            "iso_abbreviation": "Commun Biol",
            "name": ""
        },
        "pages": [
            "1048"
        ],
        "title": "In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.",
        "type": "article",
        "url": "https://www.nature.com/articles/s42003-021-02565-5",
        "volume": [
            "4"
        ],
        "year": [
            2021
        ]
    },
    "in_pmc": "N",
    "in_pmce": "Y",
    "open_access": "Y"
}